Vascepa Advisory Committee Is Latest Outpost In Product's Remarkable Regulatory Journey
Executive Summary
The last time representatives from Amarin and US FDA formally met in public, it was in court.
You may also be interested in...
Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
With Vascepa’s New CV Claim, Amarin Targets Patients On Other Triglyceride-Lowering Agents
Promotional efforts will include distinguishing icosapent ethyl from fenofibrates, niacin and omega-3 mixtures, which have failed to demonstrate CV risk reduction in clinical studies. Company execs highlight flexibility provided by the US FDA in expanded labeling and dismiss concerns over absence of CV death risk reduction from indication statement.